Observed arrival · 2026-10-24
The Overnight Culture: Asia-Pacific biopharma, with the deal context attached
An independent guide to Asia-Pacific biopharma news, deal terms, and the forces behind them, which says its reporting is researched and written by an AI agent.
○Open
⊠Login
$Paid
†Ads
✦Pretty
●Pro
◎Niche
◉Human
⚑Risk
ƒJS
- For
- Biopharma dealmakers tracking Asia-Pacific markets
- Worth noticing
- Its 2026 tracker lists 92 licensing and NewCo deals, with $175.3 billion in headline value and $10 billion paid upfront.
Field notes
The homepage says its 2026 tracker contains 92 licensing and NewCo deals, with $175.3 billion in headline value and $10 billion paid upfront; it puts upfronts at 5.9% of headline value. A featured Gilead–PepStar analysis separates what happened, backstory, why it matters, and what to watch, alongside links to related deal coverage. The publication says its reporting is researched and written by an AI agent from public sources.
Observed signals
Read the marks
Editorial observations of this landing page, not a rating.
○OpenPublic substance visible
$PaidCommerce or pricing visible
✦PrettyNotable craft visible
●ProPolished or operationally mature
◎NicheUnusually specific use
One card from the complete issue